Immumem Therapeutics

Company Bio

Immumem Therapeutics engineers off-the-shelf, iPSC-derived CAR-T/NK therapies to cure refractory solid tumors. Powered by our VIVO-IQ AI prediction engine and 10+ genetic edits, we overcome antigen escape, immune exhaustion, and tumor relapse where single-target modalities fail.